Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
about
Interferon alpha for the adjuvant treatment of cutaneous melanomaStage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literatureChinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)The past, present and future of immunotherapy against tumorSonography of the primary cutaneous melanoma: a reviewStable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells.Malignant melanoma (non-metastatic).Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.Utility of adjuvant systemic therapy in melanoma.Melanoma in pediatric, adolescent, and young adult patients.Cutaneous melanoma: new advances in treatment.Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette-Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous MelanomaMolecular alterations in clinical stage III cutaneous melanoma: Correlation with clinicopathological features and patient outcome.Immunologic functions as prognostic indicators in melanomaOutcome after therapeutic lymph node dissection in patients with unknown primary melanoma siteExamining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data.Multimarker reverse transcriptase-polymerase chain reaction assay in lymphatic drainage and sentinel node tumor burden.Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia GroupInfluence of genetic variants in type I interferon genes on melanoma survival and therapy.Value of sentinel node status as a prognostic factor in melanoma: prospective observational studyThe clinicopathological and gene expression patterns associated with ulceration of primary melanomaSerologic evidence of autoimmunity in E2696 and E1694 patients with high-risk melanoma treated with adjuvant interferon alfaSystematic review of medical treatment in melanoma: current status and future prospects.Adjuvant therapy: melanomaInterferon Alpha Signalling and Its Relevance for the Upregulatory Effect of Transporter Proteins Associated with Antigen Processing (TAP) in Patients with Malignant Melanoma.The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple techniqueClinical and immunologic basis of interferon therapy in melanoma.Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?Adjuvant treatment of melanomaUpdate on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance.Adjuvant immunotherapy of melanoma and development of new approaches using the neoadjuvant approachTreatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.Adjuvant therapy of melanoma with interferon: lessons of the past decadeAdjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.Metastatic melanoma - a review of current and future drugsLong-term pegylated interferon-alpha and its potential in the treatment of melanomaPrognostic significance of autoimmunity during treatment of melanoma with interferon.Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
P2860
Q24201908-477E3C46-739D-40B2-91C6-55114EBEEFD4Q26745767-2019175C-2798-432D-900B-80B5ADD6FAE9Q26770492-2F101664-4FFD-40EF-8470-68A6654BD904Q26799896-F7A7922A-B893-442F-8B3F-2C85177C7743Q30468180-425237A7-2808-4A91-8CCF-0BA965C8FE84Q33364273-0251A388-8CCC-4F05-9CDF-5BA8D471E48FQ33448157-8D9B0B0D-4BBE-4050-AF5A-014C958E7219Q33464837-DB259736-0315-4F74-995E-EF1EE66F3171Q33484065-4C1FFBB8-29FA-4C20-ADB9-59CA3B66F63BQ33554622-BBC70A45-1504-4741-B261-86AE62D9A797Q33558587-CB37AF29-85A0-4CE1-A4C0-17C881DE9901Q33741471-D110D298-DA3E-44D0-BF4F-7F1D75971A89Q33778554-0E7565BC-DDB1-41A2-A0DC-C2563DC333A7Q33835011-036B8D10-53E0-4519-8403-A6E7E94EC3EBQ33911465-8982DBF5-F9FF-4E04-BE12-5B5D534D713EQ34035015-A108F0DB-0FE1-4F53-9E13-72557DB4C97CQ34372934-5341438E-BBCE-42B7-9DE9-41A3E63396F3Q34484199-9EB27347-3109-47D6-96B8-5C77758FA3FDQ34500626-FD25E2BD-E06C-4508-91AC-507328F4B330Q34683580-6B0F2646-6EE4-4CD3-B24C-2645132ED884Q34772146-F278C271-110F-44F3-AA07-149A46FFA2E4Q35020518-062CDD1F-C8EF-4571-B11E-4194C7F657C1Q35584299-7FFD8C62-4E4D-4B9B-9C01-153DC32D3AAEQ35636225-C0DE6A7E-91AA-4CFF-8260-3FB9D885CD82Q35886748-676E23B2-9CF3-4CA4-81DB-611ADD3D95BBQ36155641-C6717FEF-16E0-4997-8A7A-ADBEBC19DA26Q36190624-DA042319-89B1-4B24-A910-94488BA003C0Q36349569-3A154BA4-222E-4EEB-A2E8-285D6613330EQ36656595-FA60BEBD-B4A5-47A6-8E90-EFE5A26772C4Q36691820-047BD08B-8748-46FA-AD7E-B98D94E1F4B5Q36844314-0E79770A-6F7B-4E68-BA5D-62F8725A1F3BQ36885544-BD2C4789-BB6B-46A1-946D-966DE2E49C4AQ37021067-8FC9D9D9-FFAE-4701-A62B-079728305832Q37225766-538209A5-3E4E-4CE4-A455-5565D5B1E4E9Q37412789-B89B48DB-9E0E-41A6-9048-759D3C4C6E9AQ37417271-2F25F786-C572-4B30-B986-8184854DFC1BQ37450733-004BF94C-164C-4A50-9A07-C505E6DC4F08Q37586916-E2E0A867-2EAA-4166-91C1-52AE6975B108Q37833559-8B8286EB-807D-432A-BBC8-8F9CD1D50BE9Q37902639-9E4F985C-B902-4611-948E-55F4590FAB0D
P2860
Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@ast
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@en
type
label
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@ast
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@en
prefLabel
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@ast
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@en
P2093
P1433
P1476
Post-surgery adjuvant therapy ...... : randomised controlled trial.
@en
P2093
Alessandro Testori
Alexander M M Eggermont
Cornelis J A Punt
Danielle Lienard
Dirk J Ruiter
EORTC Melanoma Group
François Sales
Gerard Groenewegen
Izabella Jagiello
Konstantin Stoitchkov
P304
P356
10.1016/S0140-6736(05)67482-X
P407
P577
2005-10-01T00:00:00Z